Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations
with INVOKANA ® (canagliflozin) Compared to Other Diabetes Medications
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 24, 2018 Category: Pharmaceuticals Source Type: news
Real-World Evidence Shows Oral INVOKANA ® (canagliflozin) Results in
Greater Weight Loss and Treatment Adherence Than Injectable GLP-1
Receptor Agonists in Type 2 Diabetes Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 23, 2018 Category: Pharmaceuticals Source Type: news
New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA ® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association’s 78th Annual Scientific Sessions
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 8, 2018 Category: Pharmaceuticals Source Type: news
Hormonal Mechanism Could Explain Canagliflozin's Fracture Risk Hormonal Mechanism Could Explain Canagliflozin's Fracture Risk
If proven, the problem might be managed by measuring 1,25-dihydroxyvitamin D levels in patients and providing calcitriol or vitamin D supplementation for those deficient.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 27, 2018 Category: Pharmaceuticals Source Type: news
Invokana Helps Kidneys Even in Diabetic CKD
(MedPage Today) -- Subanalysis of CANVAS program shows slower progression, fewer events (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 13, 2018 Category: Cardiology Source Type: news
INVOKANA ® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 12, 2018 Category: Pharmaceuticals Source Type: news
Canagliflozin May Have Most Benefit in Diabetes With HF: CANVAS Canagliflozin May Have Most Benefit in Diabetes With HF: CANVAS
Exploratory analysis of CANVAS data shows canagliflozin reduced HF hospitalization and cardiovascular death in type 2 diabetes regardless of HF status, and hints at even more benefit for those with HF.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
INVOKANA ® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2018 Category: Pharmaceuticals Source Type: news
New Late-Breaking XARELTO ® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology's Annual Scientific Session
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 26, 2018 Category: Pharmaceuticals Source Type: news
Canagliflozin Linked to Fewer HF Admissions Than Other Type 2 Diabetes Drugs Canagliflozin Linked to Fewer HF Admissions Than Other Type 2 Diabetes Drugs
Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 20, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting
RARITAN, N.J. and NEW ORLEANS, Nov. 3, 2017 -- (Healthcare Sales & Marketing Network) -- Janssen Research & Deve... Biopharmaceuticals, Nephrology Janssen, INVOKANA, canagliflozin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2017 Category: Pharmaceuticals Source Type: news
CANVAS: No Difference in Canagliflozin Effects by Prior CV Status CANVAS: No Difference in Canagliflozin Effects by Prior CV Status
A new analysis of CANVAS finds that canagliflozin reduces CV and renal risks whether the type 2 diabetes patients had prior CVD or not, although a discussant queries benefit in primary prevention.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
New Real-World Analysis Shows INVOKANA ® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 17, 2017 Category: Pharmaceuticals Source Type: news
INVOKANA ® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 14, 2017 Category: Pharmaceuticals Source Type: news
